Literature DB >> 16917905

Alzheimer dementia caused by a novel mutation located in the APP C-terminal intracytosolic fragment.

J Theuns1, E Marjaux, M Vandenbulcke, K Van Laere, S Kumar-Singh, G Bormans, N Brouwers, M Van den Broeck, K Vennekens, E Corsmit, M Cruts, B De Strooper, C Van Broeckhoven, R Vandenberghe.   

Abstract

Since the first report showing that Alzheimer disease (AD) might be caused by mutations in the amyloid precursor protein gene (APP), 20 different missense mutations have been reported. The majority of early-onset AD mutations alter processing of APP increasing relative levels of Abeta42 peptide, either by increasing Abeta42 or decreasing Abeta40 peptide levels or both. In a diagnostic setting using direct sequence analysis, we identified in one patient with familial early-onset AD a novel mutation in APP (c.2172G>C), predicting a K724N substitution in the intracytosolic fragment. The mutation is located downstream of the epsilon-cleavage site of APP and is the furthermost C-terminal mutation reported to date. In vitro expression of APP K724N cDNA showed an increase in Abeta42 and a decrease in Abeta40 levels resulting in a near three-fold increase of the Abeta42/Abeta40 ratio. Further, in vivo amyloid positron emission tomography (PET) imaging revealed significantly increased cortical amyloid deposits, supporting that in human this novel APP mutation is likely causing disease. (c) 2006 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16917905     DOI: 10.1002/humu.20402

Source DB:  PubMed          Journal:  Hum Mutat        ISSN: 1059-7794            Impact factor:   4.878


  26 in total

1.  Whatever happened to Pittsburgh Compound-A?

Authors:  William E Klunk; Chester A Mathis
Journal:  Alzheimer Dis Assoc Disord       Date:  2008 Jul-Sep       Impact factor: 2.703

Review 2.  The vexing complexity of the amyloidogenic pathway.

Authors:  Manuel A Castro; Arina Hadziselimovic; Charles R Sanders
Journal:  Protein Sci       Date:  2019-04-11       Impact factor: 6.725

Review 3.  Development of positron emission tomography β-amyloid plaque imaging agents.

Authors:  Chester A Mathis; N Scott Mason; Brian J Lopresti; William E Klunk
Journal:  Semin Nucl Med       Date:  2012-11       Impact factor: 4.446

Review 4.  Central and Peripheral Metabolic Defects Contribute to the Pathogenesis of Alzheimer's Disease: Targeting Mitochondria for Diagnosis and Prevention.

Authors:  Yunhua Peng; Peipei Gao; Le Shi; Lei Chen; Jiankang Liu; Jiangang Long
Journal:  Antioxid Redox Signal       Date:  2020-03-16       Impact factor: 8.401

5.  The familial Alzheimer's disease APPV717I mutation alters APP processing and Tau expression in iPSC-derived neurons.

Authors:  Christina R Muratore; Heather C Rice; Priya Srikanth; Dana G Callahan; Taehwan Shin; Lawrence N P Benjamin; Dominic M Walsh; Dennis J Selkoe; Tracy L Young-Pearse
Journal:  Hum Mol Genet       Date:  2014-02-12       Impact factor: 6.150

Review 6.  Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.

Authors:  Ann D Cohen; Gil D Rabinovici; Chester A Mathis; William J Jagust; William E Klunk; Milos D Ikonomovic
Journal:  Adv Pharmacol       Date:  2012

Review 7.  The future of amyloid-beta imaging: a tale of radionuclides and tracer proliferation.

Authors:  William E Klunk; Chester A Mathis
Journal:  Curr Opin Neurol       Date:  2008-12       Impact factor: 5.710

8.  Genetics of Alzheimer disease in the pre- and post-GWAS era.

Authors:  Nilüfer Ertekin-Taner
Journal:  Alzheimers Res Ther       Date:  2010-03-05       Impact factor: 6.982

Review 9.  Understanding the roles of mutations in the amyloid precursor protein in Alzheimer disease.

Authors:  S Hunter; C Brayne
Journal:  Mol Psychiatry       Date:  2017-11-07       Impact factor: 15.992

Review 10.  Genetics of Alzheimer's disease: a centennial review.

Authors:  Nilüfer Ertekin-Taner
Journal:  Neurol Clin       Date:  2007-08       Impact factor: 3.806

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.